Recent patents on biotechnology最新文献

Personalized medicine is an evolving paradigm that aims to tailor therapeutic interventions to individual patient characteristics. With a growing understanding of the genetic, epigenetic, and molecular mechanisms underlying diseases, tailored therapies are becoming more feasible and effective. This review highlights the significant advancements in personalized medicine, focusing specifically on pharmacological strategies. The article explores the integration of genomics, transcriptomics, proteomics, and metabolomics in drug development and therapy optimization. Pharmacogenomics, the customization of drug therapy based on an individual's genetic makeup, receives particular emphasis. This leads to the identification of specific biomarkers that can predict therapeutic response, drug toxicity, and susceptibility to various diseases. Together with computational tools and artificial intelligence, these advancements contribute to tailored treatment plans for patients with conditions such as cancer, cardiovascular diseases, and neurological disorders. We also highlight the challenges and ethical considerations in implementing personalized medicine, such as data privacy, cost-effectiveness, and accessibility. We outline future prospects and ongoing research in this field, highlighting the importance of collaborative efforts between researchers, clinicians, pharmacists, and regulatory authorities.

Background: Trophoblast Cell Surface Antigen 2 (Trop2) is a transmembrane glycoprotein that has been implicated in the progression and metastasis of various cancers, including hepatocellular carcinoma (HCC). Targeting Trop2 expression may represent a promising approach for the development of novel therapeutic strategies.

Objectives: This study aimed to investigate the effects of Trop2 knockdown using small interfering RNA (siRNA) on the phenotypic and molecular characteristics of the HepG2 liver cancer cell line.

Methods: HepG2 cells were transfected with different concentrations of Trop2-targeting siRNA (3 nM, 5 nM, and 7 nM) at various time intervals (6, 24, and 48 hrs). The expression of Trop2 was assessed by real-time PCR before and after transfection. The impact of Trop2 knockdown on cell apoptosis, migration, morphology, histopathological features, wound-healing assays, and microscopic analysis was examined. Additionally, the expression of the TPM1 gene was evaluated using immunohistochemical analysis.

Results: Trop2 mRNA level was significantly decreased in HepG2 cells in a time- and concentration-dependent manner following siRNA transfection. The downregulation of Trop2 resulted in a marked increase in apoptosis, a reduction in cell migration, and alterations in cell morphology and histopathological characteristics. Furthermore, the expression of the TPM1 gene was found to be upregulated in Trop2-knockdown HepG2 cells.

Conclusion: These results highlight the potential of Trop2 as a therapeutic target for the management of hepatocellular carcinoma.

The utilization of medicinal plants in the treatment of respiratory diseases has a rich history dating back centuries. A vast body of research literature, including review articles, research papers, case studies, patents, and books, provides substantial evidence supporting the use of medicinal plants in the treatment of diseases and injuries. This study delves into the diverse range of plant species known for their therapeutic properties, with a specific focus on their applications in respiratory health. Medicinal plants have played a crucial role as a source of ingredients for medications and the synthesis of drugs. Globally, over 35,000 plant species are employed for medicinal purposes, particularly in emerging countries where traditional medicine, predominantly plant-based pharmaceuticals, serves as a primary healthcare resource. This review highlights the significance of medicinal plants, such as aloe, ginger, turmeric, tulsi, and neem, in treating a wide array of common respiratory ailments. These plants contain bioactive compounds, including tannins, alkaloids, sugars, terpenoids, steroids, and flavonoids, which have diverse therapeutic applications. Some medicinal plants, notably Echinacea purpurea and Zingiber officinale, exhibit potential for adjuvant symptomatic therapy in respiratory conditions, such as chronic obstructive pulmonary disease (COPD), bronchitis, asthma, the common cold, cough, and whooping cough. The leaves of medicinal plants like Acacia torta, Ocimum sanctum, Mentha haplocalyx, Lactuca virosa, Convolvulus pluricaulis, and Acalypha indica are commonly used to address pneumonia, bronchitis, asthma, colds, and cough. This review aims to shed light on specific medicinal plants with therapeutic value, providing valuable insights for researchers in the field of herbal medicine. These plants hold the potential to serve as novel therapeutic agents in the treatment of respiratory diseases.

Background: Parthenium hysterophorous and Lantana camara are notable for their significant phytochemical and antimicrobial properties. Advancements in phytochemical research have led to the development of novel formulations and products derived from P. hysterophorus and L. camara. For instance, patent extracts from these plants have been utilized in the formulation of pharmaceutical drugs, herbal supplements, cosmeceuticals, and agricultural products. P. hysterophorous, commonly known as Santa Maria feverfew or Congress grass, contains various bioactive compounds like terpenoids, flavonoids, phenolics, and alkaloids.These compounds are the key to its medicinal properties, particularly its antimicrobial activity. On the other hand, L. camara, often referred to as wild sage, is rich in phytochemicals such as terpenoids, flavonoids, and alkaloid glycosides.

Methods: P. hysterophorous and L. camara plants selected and checking their antimicrobial activity by agar well diffusion method.

Results: In our study, we found that the leaf extract of P. hysterophorous exhibited the most potent antibacterial activity against E. coli. P. hysterophorous exhibited the most potent antifungal activity against A. niger and T. viride, with a diameter of inhibition zone measuring 12 mm, followed by A. flavus and A. parasiticus. In case of L. camara, the inhibitory zone ranging from 14 to 18 mm was detected against S. abony, P. aeruginosa, E. coli, and K. pneumonia. The leaf extract of the maximum zone of inhibition in case of L. camara was shown by A. flavus (12 mm).

Conclusion: The present study suggests that these two weeds could be useful in the development of bactericides and fungicides.

Introduction/objective: During the 1150 days of COVID-19 pandemic there were great efforts to develop efficient treatments for the disease. After this long time, some drugs emerged as treatment for COVID-19. Some of them are new drugs, most of them, known drugs. These developments were triggered by information already available in patent documents. Pharmaceutical companies, therefore, rushed to conduct drugs evaluations and trials in order to deliver to the world a reasonable treatment that could reach the majority of its population. However, it is not immediately clear how companies operated to reach their goals. The ability of open innovation to achieve results assertively and faster than closed innovation strategies is questioned and therefore, it is questioned whether pharmaceutical companies use open innovation to face COVID-19.

Methods: In this work, data available on patent databases were mined to inform about the scientific and technological panorama of selected drugs tested for COVID-19 treatment and to understand the perspectives of such developments during the pandemic.

Results: This study evidenced that most treatments were based on known drugs, that some of the initially promising drugs were abandoned during the pandemic, and that it was able to inform if open innovation and collaborations were explored strategies.

Conclusion: This study evidenced that the developments during COVID-19 were not based on open innovation by revealing a patent race towards the treatment development, but with practically no collaborations or information exchange between companies, universities, and research facilities.

Aim: This research concerns the patentability of carvacrol; it could be helpful for researchers to easily identify any innovation in the biotechnological application of this monoterpene as well as other similar compounds.

Background: Like thyme or oregano, several plants in the Lamiaceae family produce carvacrol. It is one of the secondary metabolites with several biological activities, including the improvement in plants' resistance and their protection. Carvacrol has many chemical properties, such as antioxidant and anti-microbial, which have made it interesting for multiple biotechnological applications in the fields of food, feed, pharmacology, and cosmetology.

Objective: We have made an attempt to demonstrate the value of carvacrol, first by studying quantitative data from patent documents, and then, through some relevant patents, we have tried to highlight the various fields of innovation related to the properties of carvacrol.

Methods: For the study, we have collected and sorted patent documents (i.e., patent applications and granted patents) from specialized patent databases, using "carvacrol" and some of its synonyms as keywords. The selected documents have included these keywords in their titles, abstracts, or claims. Then, thanks to patent analysis, we have tried to provide an overview of the useful properties of organic compounds.

Results: We have shown that about 90% of the patent documents studied have been published in the 2000s. The number of publications, which is constantly increasing, demonstrates the growing interest in carvacrol. Although the applications of carvacrol are varied, the data on the IPC classification show that most published innovations are concerned with formulations in the fields of health, food, and feed. The study of the most relevant patents has allowed us to highlight some developments in the extraction and synthesis of carvacrol and some examples of patents that illustrate the wide possibilities offered by the exploitation of carvacrol. Thus, we have discussed its use in the cosmetic, pharmaceutical, food, and agricultural fields.

Conclusion: Carvacrol is a natural compound with beneficial properties. Several applications using this monoterpene have already been patented in different fields. However, the evolution of patentability has grown this past year and revealed the potential of carvacrol in biotechnology.

Antibiotics are considered "wonder drugs" due to the fact that they are the most extensively utilised medication in the world. They are used to cure a broad spectrum of diseases and lethal infections. A variety of bacteria and fungi produce antibiotics as a result of secondary metabolism; however, their production is dominated by a special class of bacteria, namely Actinobacteria. Actinobacteria are gram-positive bacteria with high G+C content and unparalleled antibiotic-producing ability. They produce numerous polyenes, tetracyclines, β-lactams, macrolides, and peptides. Actinobacteria are ubiquitous in nature and are isolated from various sources, such as marine and terrestrial endophytes of plants and air. They are studied for their relative antibiotic-producing ability along with the mechanism that the antibiotics follow to annihilate the pathogenic agents that include bacteria, fungi, protozoans, helminths, etc. Actinobacteria isolated from endophytes of medicinal plants have amassed significant attention as they interfere with the metabolism of medicinal plants and acquire enormous benefits from it in the form of conspicuous novel antibiotic-producing ability. Actinobacteria is not only an antibiotic but also a rich source of anticancer compounds that are widely used owing to its remarkable tumorigenic potential. Today, amongst Actinobacteria, class Streptomyces subjugates the area of antibiotic production, producing 70% of all known antibiotics. The uniqueness of bioactive Actinobacteria has turned the attention of scientists worldwide in order to explore its potentiality as effective "micronanofactories". This study provides a brief overview of the production of antibiotics from Actinobacteria inhabiting patent environments and the methods involved in the screening of antibiotics.

Background: Diabetic peripheral neuropathy (DPN) is a complication of diabetes that occurs in 40 - 60 million individuals worldwide and is associated with other chronic diseases. However, there are no review studies that present the state-of- the- art and technologies developed to circumvent this important health problem.

Materials and methods: This review was conducted based on scientific papers and patents. The papers were retrieved from Lilacs, PubMed, and Web of Science databases, and the patents from INPI, ESPACENET, WIPO, and GOOGLE PATENTS. Thus, a sample consisting of 14 scientific articles and 667 patents was analyzed.

Results: From the analysis of the data, we drew an overview of the development of biomedical technologies for DPN and detected the pioneering spirit of China, the USA, and Japan in the area, with a focus on the treatment of DPN. Based on this, we carried out a SWOT analysis to help direct future efforts in the area, which should focus primarily on developing technologies for prevention, early diagnosis, and, above all, cure of the disease to reduce the important impact of this disease in various sectors of society.

Conclusion: This study finds a concentration of diabetic peripheral neuropathy products, especially therapeutic drugs, in high-income countries. It highlights the need for global collaboration and strategic focus on therapeutic adherence and preventive strategies to effectively manage DPN.

Since ancient times, plants have been used as a remedy for numerous diseases. The pharmacological properties of plants are due to the presence of secondary metabolites like terpenoids, flavonoids, alkaloids, etc. Anthraquinones represent a group of naturally occurring quinones found generously across various plant species. Anthraquinones attract a significant amount of attention due to their reported efficacy in treating a wide range of diseases. Their complex chemical structures, combined with inherent medicinal properties, underscore their potential as agents for therapy. They demonstrate several therapeutic properties such as laxative, antitumor, antimalarial, antibacterial, antifungal, antioxidant, etc. Anthraquinones are found in different forms (derivatives) in plants, and they exhibit various medicinal properties due to their structure and chemical nature. The precursors for the biosynthesis of anthraquinones in higher plants are provided by different pathways such as plastidic hemiterpenoid 2-C-methyl-D-erthriol4-phosphate (MEP), mevalonate (MVA), isochorismate synthase and polyketide. Anthraquinones possess several medicinal properties and a complex biosynthetic pathway, making them good candidates for patenting new products, synthesis methods, and biotechnological production advancements. By conducting a thorough analysis of scientific literature, this review provides insights into the intricate interplay between anthraquinone biosynthesis and its broad-ranging contributions to human health.

Background: In nature, orchid plants are obligate myco-heterotrophs, and rely on mycorrhizal nutrient resources to grow and sustain in the wild, until they become physiologically active photosynthetic plants. Their seeds lack nutrient reserves and receive the necessary carbon from symbiotic fungi during germination. A mycorrhizal fungus provides nutrients, especially sugars, as well as water to the corresponding host plant. The range and distribution of orchid mycorrhizal fungi influence the survivability of orchid populations in their natural habitats. Mycorrhizae form symbiotic connections with the parenchymatous tissues of the roots of orchid plants. That the symbiotic orchid mycorrhiza can invade through roots of orchid seedling, raised in vitro, has been patented.

Objective: The objective of this study was to examine the presence of mycorrhiza in the roots of Aerides multiflora during the vegetative phase.

Methods: Fresh roots were hand-sectioned, and thin sections were observed under the microscope to locate the presence of mycorrhiza. Simultaneously, to observe the expansion of mycorrhiza in the cortical region.

Results: During the vegetative phase of plant growth, a peloton-like structure forms within the cortical region of the orchid roots. Mycorrhizae was observed to be distributed throughout the cortical layer of the root.

Conclusion: This communication reviews the role of mycorrhiza in orchid plants.